Passive immunity in prevention and treatment of infectious diseases

Citation
Ma. Keller et Er. Stiehm, Passive immunity in prevention and treatment of infectious diseases, CLIN MICROB, 13(4), 2000, pp. 602
Citations number
190
Language
INGLESE
art.tipo
Review
Categorie Soggetti
Microbiology
Journal title
CLINICAL MICROBIOLOGY REVIEWS
ISSN journal
0893-8512 → ACNP
Volume
13
Issue
4
Year of publication
2000
Database
ISI
SICI code
0893-8512(200010)13:4<602:PIIPAT>2.0.ZU;2-W
Abstract
Antibodies have been used for over a century in the prevention and treatmen t of infectious disease. They are used most commonly for the prevention of measles, hepatitis A, hepatitis B, tetanus, varicella, rabies, and vaccinia . Although their use in the treatment of bacterial infection has largely be en supplanted by antibiotics, antibodies remain a critical component of the treatment of diptheria, tetanus, and botulism. High-dose intravenous immun oglobulin can be used to treat certain viral infections in immunocompromise d patients (e.g., cytomegalovirus, parvovirus B19, and enterovirus infectio ns). Antibodies may also be of value in toxic shock syndrome, Ebola virus, and refractory staphylococcal infections. Palivizumab, the first monoclonal antibody licensed (in 1998) for an infectious disease, cart prevent respir atory syncytial virus infection in high-risk infants. The development and u se of additional monoclonal antibodies to key epitopes of microbial pathoge ns may further define protective humoral responses and lead to new approach es for the prevention and treatment of infectious diseases.